India’s Serum Institute Starts Manufacturing Codagenix’s Potential Covid-19 Vaccine

Serum Institute of India has started manufacturing the U.S. biotech firm’s potential Covid-19 vaccine and it expects to begin early-stage human trial of the vaccine by the end of 2020 in the UK.

Codagenix has joined hands with the Serum Institute of India, the world’s largest vaccine maker by number of doses produced, to develop CDX-005.

Serum Institute will initiate manufacturing for large-scale safety and efficacy studies, in addition to preparing to meet global vaccine supply requirements, the pharma major said.

Serum Institute is working on several vaccine candidates for the novel coronavirus – including potentially mass-producing the one from AstraZeneca-Oxford University that has garnered global headlines – as well as developing its own.

Meanwhile, more than 150 potential vaccines are being developed and tested globally, with 38 in human trials, and candidates from ModernaInc, Pfizer Inc and AstraZeneca Plc are already in late-stage trials.